Results 131 to 140 of about 1,251,690 (298)
Arthritis Care &Research, EarlyView.Objective Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta‐analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE ...
Zahraa Qamhieh +5 more
wiley +1 more source
Arthritis Care &Research, EarlyView.People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source
A systematic review of observational studies evaluating costs of adverse drug reactions
ClinicoEconomics and Outcomes Research, 2016 Francisco Batel Marques,1,2 Ana Penedones,1,2 Diogo Mendes,1,2 Carlos Alves,1,2 1CHAD – Centre for Health Technology Assessment and Drug Research, AIBILI – Association for Innovation and Biomedical Research on Light and Image, 2School of ...
Batel Marques F +3 more
doaj
Arthritis Care &Research, EarlyView.Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source
Does Medicare Part D Protect the Elderly from Financial Risk? [PDF]
The Medicare Modernization Act of 2003 added the Part D prescription drug benefit to the Medicare program. This addition, which became effective in 2006, increased Medicare program costs by more than 10 percent in order to provide, for the first time ...
Gary V. Engelhardt, Jonathan Gruber
core +1 more source
Monograph no. 14: Working estimates of the social costs per gram and per user for cannabis, cocaine, opiates and amphetamines. [PDF]
, 2007 This work represents a first step in estimating the different social costs associated with different illicit drugs. More specifically, the report sets out in detail the annual costs in Australia (circa 2004) associated with opiates, amphetamines, cocaine,
Moore, Timothy
core
Arthritis Care &Research, EarlyView.Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer +4 more
wiley +1 more source
مدیریت اطلاعات سلامت, 2016 Introduction: Medication and its cost in the country's health care system are of grave importance. Thus, the aim of this study was to investigate the increase in medication costs in comparison to the increase in medication funding per capita of the ...
Hosseinali Ghasemi, Mahdieh Raeeszadeh
doaj
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. [PDF]
Pharmacoecon Open, 2021 Cramer-van der Welle CM +4 more
europepmc +1 more source
Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act [PDF]
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity.
Frank R. Lichtenberg, Joel Waldfogel
core